Market Trends of China Bariatric Surgery Industry
This section covers the major market trends shaping the China Bariatric Surgery Market according to our research experts:
The Stapling Devices Segment is Expected to Hold a Major Market Share in the China Bariatric Surgery Market
The stapling devices segment is expected to show a comparatively higher growth rate over the forecast period than other devices used in bariatric surgeries. It is one of the most commonly used devices. It tends to result in greater and more consistent weight loss among patients and a more significant reduction in obesity-related health problems.
According to a study published in the Global Health Journal in September 2022, obesity has become a severe public health problem. China has the world's largest number of people with obesity or overweight. More than 50% of adults and about 20% of children and adolescents in China are overweight or obese. Over the past 20 years, China has made many efforts in obesity intervention while obesity rates continued rising. Thus, owing to the increasing prevalence of obesity, which results in more surgeries, the segment is expected to show significant growth during the forecast period.
Moreover, as per the NBS (China) and MOH (China) data updated in October 2021, the total expenditure on health care in China reached over 7.2 trillion RMB (about 999 billion USD) in 2020. The figure included government spending, collective spending, and private out-of-pocket spending on health care. These are expected to increase the adoption of advanced medical devices in surgeries, including surgical staplers, in the country.
Thus, due to the abovementioned factors, the stapling devices segment is expected to grow during the forecast period.
The Gastric Balloons Segment is Expected to Record a High CAGR During the Forecast Period
A gastric balloon, also referred to as an intragastric balloon (IGB) or a stomach balloon, is an inflatable medical tool that is momentarily inserted into the stomach to aid in weight loss. The introduction of new products, increased patient awareness, collaboration with bariatric surgery centers, and manufacturing optimization to increase operating leverage are some of the factors driving the demand for gastric balloons in the bariatric surgery market within China.
As per the press release by the Beijing Friendship Hospital, in March 2021, the first gastric balloon, the "Spheria intragastric balloon," was successfully implanted into the stomach of a patient in China. The Spheria intragastric balloon was developed and manufactured by Changzhou Zhishan Medical Technology Co. Ltd. It is the first completely non-invasive weight loss medical device in the country that does not require endoscopy, anesthesia, or surgery. Currently, according to the update by the company, in November 2021, the clinical trial for esibsic (the effectiveness and safety of the intragastric balloon system in China) was underway. Such instances are expected to boost the growth of the market segment over the forecast period.
Moreover, according to the clinicaltrials.gov update, as of December 2022, there are currently eight clinical trials going on for gastric balloons in China. Thus, increasing research and development in the country is expected to boost the growth of the segment during the forecast period. Due to the abovementioned factors, the gastric balloon segment is expected to grow during the forecast period.